{"id":"bms-986504","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, BMS-986504 allows T cells to recognize and attack cancer cells more effectively. This mechanism is similar to other PD-1 inhibitors, such as nivolumab and pembrolizumab, which have shown efficacy in various types of cancer. However, the specific effects of BMS-986504 may vary depending on the type of cancer and individual patient characteristics.","oneSentence":"BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:41.671Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT07492680","phase":"PHASE2","title":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","status":"NOT_YET_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-07-17","conditions":"Solid Tumors","enrollment":260},{"nctId":"NCT07076121","phase":"PHASE2, PHASE3","title":"A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-23","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":470},{"nctId":"NCT06855771","phase":"PHASE2","title":"A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-09","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT07283705","phase":"PHASE2","title":"A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-18","conditions":"Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer","enrollment":60},{"nctId":"NCT07063745","phase":"PHASE2, PHASE3","title":"A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-01-02","conditions":"Metastatic Non-small Cell Lung Cancer With MTAP Deletion","enrollment":590},{"nctId":"NCT07382544","phase":"PHASE1","title":"Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-02-12","conditions":"Advanced Cancer, Solid Tumor","enrollment":36},{"nctId":"NCT07077434","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-15","conditions":"Advanced Solid Tumors","enrollment":32},{"nctId":"NCT06883747","phase":"EARLY_PHASE1","title":"Clinical Trial of BMS-986504 in Recurrent GBM Patients","status":"RECRUITING","sponsor":"Nader Sanai","startDate":"2025-04-28","conditions":"Glioblastoma WHO Grade IV","enrollment":9},{"nctId":"NCT06672523","phase":"PHASE1","title":"A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-03-24","conditions":"Advanced Solid Tumors With Homozygous MTAP Deletion","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MRTX1719"],"phase":"phase_2","status":"active","brandName":"BMS-986504","genericName":"BMS-986504","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986504 is a PD-1 inhibitor, which works by blocking the PD-1 receptor on T cells to enhance immune response against cancer cells. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}